Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other common onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Sébastien, Chami, Rose, Deyell, Rebecca J., El Demellawy, Dina, Ellezam, Benjamin, Jabado, Nada, Morgenstern, Daniel A., Narendran, Aru, Sorensen, Poul H. B., Wasserman, Jonathan D., Yip, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903261/
https://www.ncbi.nlm.nih.gov/pubmed/33435412
http://dx.doi.org/10.3390/curroncol28010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903261/
https://www.ncbi.nlm.nih.gov/pubmed/33435412
http://dx.doi.org/10.3390/curroncol28010038

Ejemplares similares